Evidence map›Paper›PMID 36125022›Full record

ArticlePharmacoepidemiology and drug safety2023

Mobile apps for quick adverse drug reaction report: A scoping review.

Edna Ribeiro Parracha, Ana Margarida Advinha, Manuel José Lopes, Sofia Oliveira-Martins

Abstract readScoping Review
In one paragraph

Article in Pharmacoepidemiology and drug safety, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Real-World Complexity of Prescribing Cascades.Basic & clinical pharmacology & toxicology · 2025
    Review
  8. Article
  9. A scoping review and expert consensus on digital determinants of health.Bulletin of the World Health Organization · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Edna Ribeiro ParrachaFaculty of Pharmacy, University of Lisbon, Lisboa, Portugal.ORCID 0000-0001-6957-6436
Ana Margarida AdvinhaCHRC - Comprehensive Health Research Centre, Lisboa, Portugal.ORCID 0000-0003-0689-276X
Manuel José LopesCHRC - Comprehensive Health Research Centre, Lisboa, Portugal.ORCID 0000-0002-7554-8041
Sofia Oliveira-MartinsFaculty of Pharmacy, University of Lisbon, Lisboa, Portugal.ORCID 0000-0002-0749-9137

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSpontaneous notification systems are essential in a post-marketing safety context. However, using this method, only about 6% of all adverse drug reactions are notified. To overcome this sub-notification problem, new methods need to be developed to improve and facilitate reporting. In this sense, the use of digital media, mainly medical mobile apps, has been presented as a powerful tool, including in pharmacovigilance. We performed a scope review to identify the available apps used to report adverse drug reactions around the world to eventually identify which of them best fits the Portuguese pharmacovigilance system.

methodsThe Joanna Briggs Institute guidelines were considered, and the framework proposed by Arksey and O'Malley was followed. All the articles that met the inclusion criteria were examined for this review. When the studies lacked in information about the app, Google was used to enhance the search for further information.

resultsA final number of five articles were included, revealing seven implemented mobile apps for adverse drug reaction report (Medwatcher, VigiBIP, Yellow Card, Bijwerking, Halmed, Med Safety, and ADR PvPi). These apps are implemented in the United States, France, United Kingdom, The Netherlands, Croatia, and India. Med Safety was originally designed for multi-region use and is implemented in 12 low and middle-income countries.

conclusionsApps are easier and faster ways of reporting. The integration of such a tool in an individual care plan would allow to maintain a complete electronic health record at both individual and global level and could be eventually seen as an added value by both health professionals and patients. A country specific version of the WEB-RADR could be a solution for Portugal, in order to introduce an app to notify ADRs at the national level, due previous successful experiences in European countries.

Indexed as

Drug-Related Side Effects and Adverse ReactionsMobile ApplicationsAdverse Drug Reaction Reporting SystemsHumansInternetPharmacovigilanceadverse drug reactionmobile appspharmacovigilancespontaneous notificationunderreporting

Identifiers

PMID36125022
PMCPMC10092107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.